Healthcare Compliance Intelligence Hub
Real-time regulatory updates from DEA, DOJ, FDA, CMS, and all 50 state medical boards — curated and analyzed by AI, reviewed by compliance experts. The only source you need to stay ahead of healthcare regulation changes.
Regulatory Intelligence Feed
101 articles published · Page 1 of 7
FDA Clarifies Direct-to-Consumer Telehealth Pharmaceutical Advertising Requirements
The FDA has provided guidance clarifying how existing pharmaceutical advertising regulations apply to direct-to-consumer (DTC) promotions conducted through telehealth platforms. This guidance emphasizes the need for truthful, balanced, and non-misleading information, particularly regarding prescription drug indications, risks, and benefits, regardless of the promotional channel.
Utah Medical Board Scrutiny Intensifies for Telehealth and Medspa Operations: Key Disciplinary Trends
The Utah Division of Occupational and Professional Licensing (DOPL) continues to actively monitor and enforce professional practice standards, with a growing focus on telehealth and medspa operations. Recent disciplinary actions highlight concerns regarding scope of practice, appropriate supervision, patient safety, and adherence to established practice guidelines, particularly in aesthetic and remote care settings. Healthcare businesses operating in Utah, especially those leveraging telehealth or offering medspa services, must ensure strict compliance with state regulations to mitigate enforcement risks.
DEA Registration Requirements for Telehealth Prescribing Across State Lines: Navigating Post-PHE Regulations
This article details the Drug Enforcement Administration (DEA) registration requirements for telehealth providers prescribing controlled substances, particularly when crossing state lines. It focuses on the evolving regulatory landscape following the COVID-19 Public Health Emergency (PHE) and the implications of the Ryan Haight Act's 'telemedicine exception.' Providers must understand the current temporary rules and proposed permanent changes to maintain compliance.
Navigating Telehealth and Scope of Practice in Dental Sleep Medicine
The integration of telehealth into dental sleep medicine presents both opportunities and regulatory complexities, particularly concerning scope of practice, patient evaluation, and treatment delivery. Healthcare providers must understand state-specific dental board regulations and professional guidelines to ensure compliant and ethical care for sleep-related breathing disorders. This article explores key considerations for dental practices leveraging telehealth for sleep medicine services.
Understanding North Dakota's Corporate Practice of Medicine Doctrine for Telehealth and Medspas
North Dakota maintains a Corporate Practice of Medicine (CPOM) doctrine, generally prohibiting corporations from employing physicians or controlling medical decisions. While not as strictly enforced as in some states, this framework significantly impacts business structures for telehealth providers and medspas, requiring careful consideration of management services organizations (MSOs) and professional corporations (PCs).
FDA Intensifies Scrutiny of Marketing Claims for Telehealth Weight Loss and Hormone Therapy Programs
The FDA is increasing its enforcement actions against companies making unsubstantiated or misleading marketing claims for telehealth-provided weight loss and hormone therapy products and services. This heightened scrutiny targets products marketed as drugs or medical devices without proper FDA approval or clearance, or those making unproven efficacy claims.
DEA Telehealth Prescribing of Controlled Substances: Navigating the Ryan Haight Act and Post-PHE Waivers
This article clarifies the Drug Enforcement Administration (DEA) requirements for prescribing Schedule II-V controlled substances via telehealth, focusing on the Ryan Haight Online Pharmacy Consumer Protection Act and the evolving landscape following the end of the COVID-19 Public Health Emergency waivers. It details the current exceptions and the DEA's proposed rules, emphasizing the necessity of an in-person medical evaluation for most controlled substance prescriptions.
Navigating State-Specific Telehealth Prescribing Requirements for GLP-1 Agonists and Other Weight Management Medications
Telehealth prescribing of weight management medications, including GLP-1 agonists like semaglutide and tirzepatide, is subject to varying state-specific regulations concerning the establishment of a valid patient-provider relationship and the necessity of an in-person examination. Providers must understand these nuanced requirements to ensure compliance and avoid regulatory scrutiny, particularly regarding controlled substance status and the prescribing of compounded versions.
Wyoming's Corporate Practice of Medicine (CPOM) Doctrine: Implications for Telehealth and Medspa Operations
Wyoming maintains a Corporate Practice of Medicine (CPOM) doctrine, generally prohibiting corporations from employing physicians or controlling medical practice. However, enforcement in Wyoming is considered flexible, allowing for certain management service organization (MSO) structures to support telehealth and medspa businesses, provided professional autonomy is preserved.
DOJ Intensifies Enforcement Against Telehealth Controlled Substance Prescribing Violations
The Department of Justice (DOJ) continues to aggressively pursue telehealth companies and practitioners involved in illegal prescribing and distribution of controlled substances, particularly opioids and stimulants. Recent enforcement actions highlight the DOJ's focus on fraudulent schemes, lack of legitimate medical purpose, and violations of the Ryan Haight Act and DEA regulations. This scrutiny necessitates robust compliance frameworks for all healthcare businesses operating in the telehealth space.
DEA Telemedicine Special Registration: Navigating Controlled Substance Prescribing for Multi-State Platforms
The Drug Enforcement Administration (DEA) has proposed rules for a special registration process that would permit practitioners to prescribe controlled substances via telemedicine without an in-person medical evaluation, subject to specific conditions. This framework aims to establish a permanent regulatory pathway following the COVID-19 public health emergency waivers, significantly impacting multi-state telehealth operations.
Interstate Chiropractic Telehealth: Navigating Licensing and Practice Limitations
Chiropractic telehealth, while expanding, faces significant limitations due to state-specific licensing requirements and varying scopes of practice, particularly regarding physical examination and diagnosis. Practitioners must ensure they are fully licensed in both their originating state and the patient's location, and understand that many states restrict chiropractic telehealth to established patients or specific consultation types.
Montana Telehealth Prescribing: Establishing a Valid Provider-Patient Relationship
Montana law outlines specific requirements for establishing a valid provider-patient relationship via telehealth, which is a prerequisite for prescribing medications. This includes initial in-person visits for certain controlled substances and clear standards for remote evaluations to ensure appropriate care and prevent fraud.
DEA Heightens Scrutiny on Online Prescribing of Controlled Substances, Including GLP-1s
The Drug Enforcement Administration (DEA) is intensifying its focus on the online prescribing of controlled substances, a trend accelerated by the COVID-19 public health emergency flexibilities. This includes a particular emphasis on medications like GLP-1 agonists, which, while not controlled substances themselves, are often prescribed in conjunction with or in a manner that draws DEA attention to broader telehealth prescribing practices.
DOJ Intensifies Anti-Kickback Statute Enforcement on Telehealth Referral and Marketing Arrangements
The Department of Justice (DOJ) is actively scrutinizing telehealth companies and their marketing partners for potential violations of the Anti-Kickback Statute (AKS), particularly concerning referral-generating arrangements. Recent enforcement actions highlight the DOJ's focus on schemes where remuneration, disguised as marketing fees or other payments, induces referrals for federally funded healthcare services. Healthcare businesses engaged in telehealth must ensure their marketing and referral agreements strictly comply with AKS to avoid severe civil and criminal penalties.
In-Depth Compliance Resources
Comprehensive guides, checklists, and templates to help you navigate healthcare compliance — from CPOM structuring to GFE requirements and medical director agreements.
The Complete Guide to Good Faith Exams
Everything you need to know about GFE requirements, best practices, and state-specific regulations.
Read guideCPOM Laws: A State-by-State Analysis
Comprehensive breakdown of Corporate Practice of Medicine laws across all 50 states.
Read guideHealthcare Compliance Checklist 2026
The definitive checklist for launching and maintaining compliant telehealth and in-person healthcare operations.
Read guidePC-MSO Formation Guide
Step-by-step guide to structuring Professional Corporations and Management Services Organizations.
Read guideMedical Director Requirements by State
State-by-state requirements for medical director oversight in telehealth, medspas, IV therapy clinics, and other healthcare operations.
Read guideGLP-1 Prescribing Compliance Guide
Regulatory requirements for GLP-1 weight loss medication prescribing via telehealth.
Read guideCollaborative Practice Agreement Templates
State-specific CPA templates and guidance for physician-NP collaborative arrangements.
Read guideStay Ahead of Every Regulatory Change
Our AI-powered intelligence engine monitors DEA, DOJ, FDA, CMS, and all 50 state medical boards so you never miss a compliance update that affects your business.